



Jubilant Pharma Limited

6 Temasek Boulevard, #20-06
Suntec City Tower Four, Singapore 038986
Tel.: +65 6235 4129
www.jubilantpharma.com

Jubilant Pharma Limited announces launch of 'JUBI-R' (remdesivir) in India for the treatment of COVID-19

Noida (UP), India, Monday, August 03, 2020

Jubilant Pharma Limited, a subsidiary of Jubilant Life Sciences Limited, is pleased to announce that, its subsidiary, Jubilant Generics Limited ("Jubilant") has launched remdesivir for injection under the brand name 'JUBI-R' in the Indian market at a price of INR 4,700 per vial of 100 mg (lyophilized injection). The Company will make the drug available to over 1,000 hospitals providing COVID-19 treatment in India through its distribution network. Jubilant's 24 hour help line will enhance access to 'JUBI-R' during these pandemic times, where timely access to the drug may prove critical to treatment outcomes.

In order to increase accessibility of 'JUBI-R' to patients below the poverty line and to front line paramedical staff, Jubilant Bhartia Foundation, a not-for-profit organisation of Jubilant Group, is launching unique programs in India aimed at distribution of the drug.

In May 2020, Jubilant entered into a non-exclusive Licensing Agreement with Gilead Sciences, Inc. (NASDAQ: GILD) that granted it the right to register, manufacture and sell Gilead's investigational drug remdesivir in 127 countries including India. Remdesivir is the only antiviral drug that has received Emergency Use Authorization (EUA) by the USFDA for treatment of suspected or laboratory confirmed COVID-19 in adults and children hospitalized with severe disease. On July 20, 2020, Jubilant received approval from the Drug Controller General of India (DCGI) to manufacture and market the investigational antiviral drug remdesivir ("JUBI-R") for 100 mg/vial (lyophilized injection) for restricted emergency use in India for the treatment of severe COVID-19. 'JUBI-R' will require to be administered intravenously in a hospital setting under the supervision of a medical practitioner.

"It gives us immense satisfaction to launch 'JUBI-R' as this drug has a potential to save precious lives across the globe. We have launched the product at affordable prices and strive to make it available in sufficient quantities to meet high demand for the drug in the Indian market and in other countries," stated **Mr. Shyam S. Bhartia, Chairman & Managing Director** and **Mr. Hari S. Bhartia, Co-Chairman, Jubilant Pharma Limited**. "The Company's ability to launch this product in such short timelines highlights our R&D and manufacturing capabilities and our continued commitment to provide leading healthcare solutions. Through the Jubilant Bhartia Foundation, we will distribute the drug on compassionate basis to save precious lives of people through unique programs."



About Jubilant Pharma Limited

Jubilant Pharma Limited (JPL), a company incorporated under the laws of Singapore and a wholly-owned subsidiary of Jubilant Life Sciences Limited, is an integrated global Pharmaceutical company engaged in manufacturing and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile Injectables and Non Sterile products through six USFDA approved manufacturing facilities in the US, Canada and India and a network of over 50 radiopharmacies in the US. The Company has a team of around 5,200 multicultural people across the globe and is committed to deliver value to its customers spread across over 75 countries. It is well recognized as a 'Partner of Choice' by leading pharmaceutical companies globally.

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.